Quick Answer
GeoVax Labs, Inc. reported Net Income of -$24.99 million for fiscal year 2024.
GeoVax Labs, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Net Income | -$24.99M +3.8% |
-$25.97M -85.2% |
-$14.02M +24.5% |
-$18.57M -527.8% |
-$2.96M -24.8% |
-$2.37M +7.4% |
| Total Assets | $8.16M -12.1% |
$9.28M -70.4% |
$31.35M +165.7% |
$11.80M +13.5% |
$10.39M +2116.8% |
$468.9K -27.0% |
| Cash and Equivalents | $5.51M -14.7% |
$6.45M -76.6% |
$27.61M +141.7% |
$11.42M +15.6% |
$9.88M +3388.3% |
$283.3K +9.1% |
| Stockholders Equity | $5.05M -12.4% |
$5.76M -78.3% |
$26.60M +509.9% |
$4.36M -54.4% |
$9.57M +707.7% |
-$1.57M -54.0% |
| R&D Expense | $23.71M +14.4% |
$20.72M +127.1% |
$9.12M -41.3% |
$15.55M +536.3% |
$2.44M +27.9% |
$1.91M +1.7% |
| Operating Income | -$25.14M +6.0% |
-$26.74M -90.6% |
-$14.03M +25.2% |
-$18.75M -565.5% |
-$2.82M -18.7% |
-$2.37M +7.4% |
| Shares Outstanding | 10.54M +432.9% |
1.98M +12.6% |
1.76M -72.5% |
6.38M +66.4% |
3.83M +25474.3% |
14,992 +6745.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$6.32M | -8.7% | -17.7% |
| Total Assets | September 30, 2025 | $6.73M | -39.4% | +25.8% |
| Cash and Equivalents | September 30, 2025 | $5.01M | -41.7% | +61.9% |
| Stockholders Equity | September 30, 2025 | $4.91M | -42.3% | +73.9% |
| R&D Expense | September 30, 2025 | $5.04M | -31.9% | +6.7% |
| Operating Income | September 30, 2025 | -$6.37M | -8.9% | -17.6% |
| Shares Outstanding | September 30, 2025 | 29.71M | +245.0% | +86.5% |
- GeoVax Labs, Inc. reported Net Income of -$24.99 million for fiscal year 2024.
- GeoVax Labs, Inc. showed an increase of +3.8% in Net Income compared to the prior fiscal year.
- GeoVax Labs, Inc. reported Total Assets of $8.16 million for fiscal year 2024.
- GeoVax Labs, Inc. showed a decrease of -12.1% in Total Assets compared to the prior fiscal year.
- GeoVax Labs, Inc. reported Cash and Equivalents of $5.51 million for fiscal year 2024.
- GeoVax Labs, Inc. showed a decrease of -14.7% in Cash and Equivalents compared to the prior fiscal year.
- GeoVax Labs, Inc. reported Stockholders Equity of $5.05 million for fiscal year 2024.
- GeoVax Labs, Inc. showed a decrease of -12.4% in Stockholders Equity compared to the prior fiscal year.
- GeoVax Labs, Inc. reported R&D Expense of $23.71 million for fiscal year 2024.
- GeoVax Labs, Inc. showed an increase of +14.4% in R&D Expense compared to the prior fiscal year.
- GeoVax Labs, Inc. reported Operating Income of -$25.14 million for fiscal year 2024.
- GeoVax Labs, Inc. showed an increase of +6.0% in Operating Income compared to the prior fiscal year.
- GeoVax Labs, Inc. reported Shares Outstanding of 10.54 million shares for fiscal year 2024.
- GeoVax Labs, Inc. showed an increase of +432.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: